PlantEXT and the Agricultural Research Organization (ARO-Israel) Isolate Cannabis Compounds That Potentially Decrease Inflammation in the Cytokine Storm of COVID-19
Receive updates straight into your inbox
PlantEXT is leveraging its proprietary technology to develop new cannabinoid medicines that serve the unmet need of patients suffering from the cause of inflammation all over the world. Based on the expertise, knowledge and skills of its renown management team and advisory board in addition to licensed technologies from world known institutions, Plantext is developing innovative anti-inflammatory solutions for a variety of medical indications. By focusing at the molecular level and developing formulations that are not strain dependent – these unique combinations of cannabinoids, terpenes, etc. will be replicated in all geographies around the world where medical marijuana is legal. PlantEXT boasts an advanced combination of a true pharma approach to medical cannabis together with an early mover advantage with patent-pending formulations.